Answers are grounded in this paper and cite their sources.
The development of therapy resistance in cancer is a complex mechanism with multifaceted and catastrophic consequences.BCRP (Breast Cancer Resistance Protein/ATP-Binding Cassette Subfamily G member 2; ABCG2), a drug efflux transporter, is recognized as a key regulator in obtaining multidrug resistance properties of cancer cells.NRF2 (Nuclear Factor Erythroid 2-Like 2; NFE2L2) plays an essential role in maintaining cellular redox homeostasis by regulating the expression of an array of antioxidant and detoxifying genes.In contrast to its protective roles in normal cells, a substantial body of evidence has demonstrated the negative aspects of NRF2 accumulation in cancer cells, including facilitated tumor growth, stemness, and therapy resistance.This review focuses on the linkage between BCRP and NRF2 in cancer and its consequences in acquiring therapy resistance.In particular, we highlight the role of the NRF2/BCRP axis in photodynamic therapy resistance and cancer stem cell maintenance, demonstrating that inhibition of this axis can be a beneficial strategy to overcome resistance to cancer therapy.A comprehensive understanding of the NRF2/BCRP regulating pathway will lead to the development of new therapeutic approaches and improve the prognosis of cancer patients.
No takes yet. Share an insight, caveat, or question.
Hallis et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: